AstraZeneca PLC (AZN)

Healthcare
Drug Manufacturers - General
United Kingdom
Yahoo Finance  •  Trading View  •  Company site
Price
$202.28
▲ 8.88 (4.59%)
Market Cap
$313,250,283,520
Shares: 1,550,283,527
P/E
N/A
P/B: N/A
ROE
N/A
Current Ratio: N/A
Fundamentals Score
25 (NEGATIVE)

Company Overview

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple next-generation therapies for obesity and type 2 diabetes; and collaboration Revna Biosciences for lung cancer treatment. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Headquarters: 1 Francis Crick Avenue, Cambridge, CB2 0AA, United Kingdom  |  Employees: N/A  |  Website: astrazeneca.com
Key Contacts
IR / Phone: 44 20 3749 5000
Exchange: NYQ
Industry: Drug Manufacturers - General
Quick Financial Snapshot
RevenueN/A
Net IncomeN/A
Free Cash FlowN/A
Book Value / ShareN/A

Balance Sheet & Liquidity

Total LiabilitiesN/A
Total EquityN/A
Debt / EquityN/A
Current RatioN/A
Interest CoverageN/A
Working CapitalN/A

Valuation Metrics

Core multiples and valuation signals — useful to compare vs peers.

P/E (TTM)N/A
Industry P/EN/A
Forward P/E34.41
P/BN/A
Price / SalesN/A
P / FCFN/A
EV / EBITDAN/A
Graham NumberN/A
DCF (placeholder)
Notes: red items typically indicate expensive multiples relative to fundamentals. Use the "Compare with industry" tool for context.

EPS (Annual)

Financial Performance

Revenue vs Net Income

Free Cash Flow (annual)

Profitability & Efficiency

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROIC N/A
Asset Turnover N/A

Automated Fundamental Signals (Score: 25)

Passed
  • Price CAGR 13.64%
Failed
  • Positive Free Cash Flow
  • DCF valuation (undefined)

Price Chart (Candlestick)

Technical Analysis (Score: 85)

RSI (14)64.01
SMA 50184.63
SMA 200161.70
MACD2.83
Signal BULLISH
RSI 64.0, SMA trend bullish, momentum 42.4%.

Governance & Management

Governance scores: Audit: N/A | Board: N/A | Compensation: N/A | Shareholder Rights: N/A
Executive Team
NameTitle
Mr. Pascal Claude Roland Soriot D.V.M., M.B.A. CEO & Executive Director (1959)
Dr. Aradhana Sarin M.D. CFO & Executive Director (1974)
Ms. Pam P. Cheng EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board (1970)
Mr. Andrew P. Barnett Head of Investor Relations (—)
Mr. Jeffrey Pott J.D. CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board (—)
Dr. Ruud Dobber Ph.D. Executive Vice-President of BioPharmaceuticals Business Unit (—)
Dr. Susan Mary Galbraith M.D., Ph.D. Executive Vice President of Oncology R&D (1966)
Ms. Iskra Reic Executive Vice President of International (—)
Governance data last updated: N/A

Latest News

No news available for this company.

← Back